These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 28430957)
1. CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients. Chen P; Chu A; Zia H; Koduru P; Collins R; Winick N; Fuda F; Chen W Am J Clin Pathol; 2016 Nov; 146(5):632-638. PubMed ID: 28430957 [TBL] [Abstract][Full Text] [Related]
2. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Gaikwad AS; Donohue RE; Elghetany MT; Sheehan AM; Lu XY; Gramatges MM; McClain KL; Mistretta TA; Punia JN; Moore TJ; Goltsova T; Cubbage M; Curry CV Int J Clin Exp Pathol; 2014; 7(9):6225-30. PubMed ID: 25337274 [TBL] [Abstract][Full Text] [Related]
3. Philadelphia chromosome-positive acute lymphoblastic leukemia: a cytogenetic study of 33 patients diagnosed between 1981 and 2008. De Braekeleer E; Douet-Guilbert N; Morel F; Le Bris MJ; Basinko A; Berthou C; Morice P; Férec C; De Braekeleer M Anticancer Res; 2010 Feb; 30(2):569-73. PubMed ID: 20332472 [TBL] [Abstract][Full Text] [Related]
5. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia. Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
7. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series. Bayrak AG; Daglar Aday A; Yavuz AS; Nalcaci M; Ozbalak MM; Cefle K; Ozturk S; Palanduz S Leuk Res; 2021 Dec; 111():106725. PubMed ID: 34634595 [TBL] [Abstract][Full Text] [Related]
8. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. Bennour A; Bellâaj H; Ben Youssef Y; Elloumi M; Khelif A; Saad A; Sennana H J Cancer Res Clin Oncol; 2011 Sep; 137(9):1329-36. PubMed ID: 21739181 [TBL] [Abstract][Full Text] [Related]
9. Acute Lymphoblastic Leukemia With Near-haploid Karyotype and Philadelphia Chromosome. Panagopoulos I; Andersen K; Wik HS; Tandsæther MR Anticancer Res; 2024 Apr; 44(4):1389-1397. PubMed ID: 38537997 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391 [TBL] [Abstract][Full Text] [Related]
11. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580 [TBL] [Abstract][Full Text] [Related]
12. Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement. Owaidah TM; Rawas FI; Al Khayatt MF; Elkum NB Hematol Oncol Stem Cell Ther; 2008; 1(1):34-7. PubMed ID: 20063526 [TBL] [Abstract][Full Text] [Related]
13. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401 [TBL] [Abstract][Full Text] [Related]
14. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Drexler HG; MacLeod RA; Uphoff CC Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072 [TBL] [Abstract][Full Text] [Related]
15. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia. Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF; Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Jaso J; Thomas DA; Cunningham K; Jorgensen JL; Kantarjian HM; Medeiros LJ; Wang SA Cancer; 2011 Sep; 117(17):4009-17. PubMed ID: 21365622 [TBL] [Abstract][Full Text] [Related]
19. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014 [TBL] [Abstract][Full Text] [Related]
20. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG). Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]